Back to top
more

Altimmune (ALT)

(Delayed Data from NSDQ)

$3.67 USD

3.67
2,535,279

+0.09 (2.51%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.66 -0.01 (-0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Do Options Traders Know Something About Altimmune (ALT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

Zacks Equity Research

Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

by Zacks Equity Research

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

Zacks Equity Research

Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

Zacks Equity Research

Company News for Jul 13, 2020

by Zacks Equity Research

Companies in the news are: BNGO, AMRX, ALT, EXPR

Zacks Equity Research

Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

Zacks Equity Research

Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

Zacks Equity Research

Company News for Mar 2, 2020

by Zacks Equity Research

Companies in the news are: ALT, BIG, W, CDXS

Zacks Equity Research

Will Altimmune (ALT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Altimmune (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.